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Abstract
Purpose of review Tuberculous meningitis (TBM) is a global health problem. In this review,
we systematically evaluate the evidence for current and emerging antimicrobials, host-
directed therapies and supportive managements.
Recent findings Current antimicrobial regimes do not factor the differing ability of drugs to
cross the blood-brain barrier. Rifampicin may be more effective at higher doses yet the
most recent clinical trial failed to demonstrate survival benefit at 15 mg/kg/day. Dose
finding studies suggest that higher doses still may be safe and more effective.
Fluoroquinolones are currently listed as important second-line agents in drug-resistant
TBM; however, a survival benefit as a first-line agent has yet to be shown. Linezolid may be
a promising antimicrobial with good central nervous system penetrance. Dexamethasone
reduces mortality in HIV-uninfected individuals yet evidence for its use in HIV co-
infection is lacking. Aspirin has anti-inflammatory and anti-thrombotic properties. Small
studies have demonstrated efficacy in reducing stroke but further research is required to
better understand its effect on controlling the host inflammatory response. Discovery of
genetic polymorphisms may direct individualized immune therapies and mediators of the
innate immune response may provide targets for the development of novel therapies.
There is at present no significant evidence base to guide management of hydrocephalus in
HIV co-infection.
Summary Further clinical trial data is required to improve treatment outcomes in TBM in
particularly in regard to the value of high-dose rifampicin, newer antimicrobials with
improved central nervous system penetration and host-directed therapies. Supportive
measures in particular the management of hydrocephalus in HIV co-infection should be
an area for future research.
Introduction
Tuberculosis remains a major global health problem. In
2015, an estimated 10.4 million new cases of TB oc-
curred worldwide. The World Health Organization’s
‘End TB Strategy’ calls for a 90% reduction in TB-
related deaths and 80% reduction in TB incidence rate
by 2030, 15 years on from its declaration. In 2015, the
rate of reduction in yearly incidence was 1.5%, which
falls below the required target of 4–5%. These figures
reflect the ongoing evolving challenges faced in the pre-
vention and treatment of tuberculosis [1].
In 1948, the modern era of tuberculosis treatment
saw the first evidence of therapeutic response to strepto-
mycin in pulmonary TB (PTB) [2]. Isoniazid followed in
1952 with a key trial demonstrating improved efficacy
when added to streptomycin [3] and in 1971 the addi-
tion of rifampicin and pyrazinamide led to reduction in
treatment duration from 2 years to 6 months [4]. How-
ever, unlike in PTB where decades of clinical trials have
instructed and refined treatment regimens in drug-
sensitive and more recently drug-resistant TB, compara-
tively, little evidence exists to guide optimal treatment in
tuberculous meningitis.
Tuberculosis meningitis (TBM) is the deadliest
form of tuberculosis withmortality highest in children
[5] and HIV-1 co-infection (40%) [6]. The combined
complications of HIV-1 co-infection and multi-drug
resistance in TBM confer a mortality close to 100% [6].
Complications of TBM such as hydrocephalus and
cerebral vasculitis add to the complexities of
treatment.
In this review, we evaluate evidence guiding the
treatment of TBM in adults. We consider three aspects
to successful management: (i) effective antimicrobial
treatments, (ii) controlling the host inflammatory re-
sponse, and (iii) supportive interventions to reduce
raised intracranial pressure. We discuss TBM complicat-
ed by HIV-1 co-infection in particular timing of antire-
troviral therapy. We consider efficacy of current
treatments, review the evidence for emerging therapies
and suggest areas for future research.
Antimicrobials
Current WHO guidelines for TBM are based on those
developed to treat PTB and suggest treatment with
2 months of rifampicin (RMP), isoniazid (INH),
pyrazinamide (PZE) and ethambutol (ETB) followed
by up to 10 months of RMP and INH for all patients
[7]. Although initiation of this regimen before the onset
of coma is the strongest predictor of survival from TBM
[8], this regimen does not take into account the differ-
ential ability of anti-tuberculosis drugs to penetrate the
brain [9].
Introduced in 1952, INH made immediate impact
on mortality in all forms of tuberculosis. This drug
penetrates the CNS freely [10] and is a key chemothera-
peutic agent in TBM with proven potent bactericidal
activity [11]. RMP does not penetrate the blood-brain
barrier (BBB) as well with concentrations in CSF only
10–20% of that reached in plasma [9]. This observation
may not reflect the amount of ‘active’ RMP; in plasma,
the majority of RMP is protein bound and only the
unbound portion is active, whereas in CSF, very little is
protein bound. The 10–20% of RMP noted in CSF may
be comparable to levels of active drug in plasma. There
has been some research into the efficacy of higher dose
RMP in TBM [12••, 13, 14]. In a randomized study
which informed the current recommended dose of
RMP, patients with PTB received either 450 mg
(7.5 mg/kg), 600 mg (10 mg/kg) or 750 mg (12.5 mg/
kg) of RMP with a fixed dose of INH. There was no
observed difference in rate of sputum conversion in
those who received 750 mg OD and 600 mg OD; how-
ever, those who received 450 mg OD showed a lower
rate of sputum conversion and a higher rate of treatment
failure [15]. More recent in vitro, animal and early
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bactericidal activity studies suggest that the 600-mg once
daily dose is at the lower end of the dose-response curve
[16]. In 2013, an open-labelled randomized phase 2
study in 60 Indonesian adults with TBM showed a
50% reduction in mortality with high dose (600 mg,
about 13 mg/kg) intravenously compared to standard
oral dose (450 mg, about 10 mg/kg) RMP. A larger
randomized placebo-controlled trial in Vietnam
recruiting between 2011 and 2014 tested a higher dose
of oral RMP alongside levofloxacin against standard
therapy and failed to show a mortality benefit with an
oral dose of 15 mg/kg [12••]. Around the same time, a
dose ranging trial conducted in PTB showed that doses
up to 35 mg/kg were safe and well tolerated in the first
2 weeks of therapy [17•]. In the same study, the highest
doses of 30 and 35 mg/kg showed highest early bacteri-
cidal activity measured by fall in colony-forming units
(CFU) and time to positivity (TTP). At 2 weeks, 8 out of
14 patients taking 35 mg/kg of RMP were culture nega-
tive compared 5 of 14 taking 20 mg/kg, 0 of 15 taking
25 mg/kg2 of 15 taking 30/kg and 3 of 8 controls [17•].
This data may suggest that the selected dose of 15mg/kg
was not high enough and provides impetus for evaluat-
ing higher doses of RMP in TBM.
Pyrazinamide (PZA) which was introduced simulta-
neous to RMP as a potential agent with a role in treat-
ment shortening [18] has good CSF penetration; con-
centrations in CSF are close to that of serum [9]. Though
PZA has poor bactericidal activity in the first 2–4 days of
treatment, studies in PTB have shown that thereafter
Table 1. Anti-tuberculous drugs in tuberculous meningitis and drug-resistant tuberculosis
First-line drugs for treatment of drug sensitive TBM in adults
Drug WHO-recommended daily dose WHO-recommended
duration
CSF penetrance
(CSF:plasma concentration)
Rifampicin 10 mg/kg (range 8–12 mg/kg);
max 600 mg
12 months 10–20%
Isoniazid 5 mg/kg (range 4–6 mg/kg);
max 300 mg
12 months 80–90%
Pyrazinamide 25 mg/kg (range 20–30 mg/kg) 2 months 90–100%
Ethambutol 15 mg/kg (range 15–20 mg/kg) 2 months 20–30%
Second-line drugs for treatment of TBM in adults
Levofloxacin 10–15 mg/kg Throughout treatment 70–80%
Moxifloxacin 400 mg Throughout treatment 70–80%
Amikacin 15 mg/kg; max 1 g. IV or IM. Intensive phase only 10–20%
Kanamycin 15 mg/kg; max 1 g. IV or IM. Intensive phase only 10–20%
Capreomycin 15 mg/kg; max 1 g. IV or IM. Intensive phase only No data (probably very low)
Ethionamide or
prothionamide
15–20 mg/kg; max 1 g. Throughout treatment 80–90%
Cycloserine 10–15 mg/kg; max 1 g Throughout treatment 80–90%
Linezolid 600 mg Throughout treatment 30–70%
Other drugs used in treatment of multi-drug-resistant TB but of uncertain benefit in TBM
Clofazimine 100 mg OD No recommended
duration
Limited data (probably low)
p-Aminosalicylic acid 200–300 mg/kg No recommended
duration
No data (probably very low)
Bedaquiline Not determined New drug. Limited
availability.
Probably very low
(but data from one patient only)
Delamanid Not determined New drug. Limited
availability.
No data
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(days 4–14), its activity matches that of INH and RMP
[19, 20].
Of the current recommended first-line drugs, pene-
tration of ethambutol (ETB) is the poorest, even when
the BBB is inflamedwhich raises the question of its value
within the treatment regimen [9].With this and the issue
of preventing INH resistance in mind, debate has arisen
regarding the choice of a fourth drug in treatment of
drug-sensitive TBM. Further urgency has been conferred
by the global rise in RIF-resistant (RR) and multi-drug
resistant TB (MDR-TB). MDR-TB is by definition infec-
tion resistant to RMP and INH; global incidence is esti-
mated at 480,000 cases per annum [21]. WHO guide-
lines for the treatment of RR- andMDR-TBM state that at
least five effective drugs should be used initially includ-
ing a fluoroquinolone and an injectable second-line
agent and treatment should last 18–24 months [21].
Recommended core second-line agents and their CSF
penetrance are listed in Table 1. In 2016, the WHO
issued guidance on standardized shorter MDR-TB regi-
mens which was based on observational data reporting
treatment with seven drugs over 9–12 months in 14
countries worldwide. The new recommendation is ex-
pected to benefit the efforts to reduce MDR-TB world-
wide although there is risk of worsening resistance (lead-
ing to extensively drug resistant TB) if the regimen is
used inappropriately [22]. There is currently no evidence
base to support use of this regimen in TBM.
Of the fluoroquinolones, ofloxacin was the first to be
recognized as a potential effective treatment for tubercu-
losis [23]. In 2011, a randomized study in Vietnam
investigated the pharmacokinetics and exposure-
response relationships of three fluoroquinolones in
TBM. A total of 61 patients were assigned to standard
treatment alone or standard therapy in combination
with either ciprofloxacin, levofloxacin or gatifloxacin
for the first 60 days of treatment. Population pharma-
cokinetic models describing the disposition of
fluoroquinolones in CSF and plasma were used to de-
termine exposure-response relationships through
univariable analysis of clinical outcomes. These revealed
consistent U-shaped exposure-response relationships for
dichotomous and time to event outcomes. Significant
higher proportions of death and disability were ob-
served for patients with lower or higher plasma and
CSF fluoroquinolone exposures than for patients with
intermediate exposures. These findings may be ex-
plained by the increased permeability of the BBB in
severe meningeal disease. It may also be a result of
reduced creatinine clearance in those with more severe
systemic involvement and therefore those more likely to
die. Nonetheless, the study demonstrated improved
clinical outcomes measured by survival, burden disabil-
ity and incidence disease relapse of fluoroquinolones
when used prior to the onset of comas and informs
dose finding for future studies to test efficacy of
fluoroquinolones in TBM [24]. In PTB, several studies
have a higher rate of sputum conversion at 2 months of
treatment with regimens containing fluoroquinolones;
however, more adverse events and less favourable clini-
cal outcomes have also been observed [25]. In PTB, the
addition of a fluoroquinolone to standard treatment did
not permit effective treatment shortening [26]. Since
2011, two studies in TBM (both discussed above) have
evaluated the efficacy of adding fluoroquinolones to
standard treatment in reducing mortality [12••, 27]. In
a randomized double-blind study, a total of 817 adults
with TBM received either standard therapy or an inten-
sified regimen including a higher dose of RMP (15 mg/
kg) as well as levofloxacin 20mg/kg. This study failed to
show a benefit of adding levofloxacin in TBM [12••].
The second study was a randomized controlled trial
undertaken in Indonesia where 60 adults with TBMwere
randomized to receive standard dose (450 mg) or high
dose (600 mg) RMP with either moxifloxacin (400 mg)
or ethambutol (750mg). This analysis demonstrated no
relationship between exposure to moxifloxacin in plas-
ma and CSF and survival [4]. Fluoroquinolones are
currently listed as core second-line agents for the treat-
ment of RR and MDR TBM; however, further large-scale
phase 3 studies are required to address the question of
survival benefit in TBM.
Linezolid, a synthetic antimicrobial and the first
agent of the oxazolidinone class, was licensed in 2000
for treatment of nosocomial pneumonia and skin infec-
tions caused by select gram-positive bacteria [28, 29].
The role of linezolid in tuberculosis was first investigated
in the context of MDR tuberculosis. Early studies report-
ed rapid sterilization of Mycobacterium tuberculosis cul-
tures following the administration of linezolid 600 mg
BD in addition to standard treatment [30–32]. Follow-
ing this, a number of studies demonstrated a role for
linezolid as an effective treatment in drug-resistant tu-
berculosis [33–38]. There may be further benefit in pa-
tients with additional resistance to fluoroquinolones
and with extensively drug-resistant TB [39]. In a systemic
review and meta-analysis conducted to assess efficacy,
safety and tolerability of linezolid in drug-resistant PTB,
15 studies including one randomized controlled trial
were identified covering 367 patients of which 239
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could be evaluated for effectiveness. Eighty-three percent
[95% confidence interval, 75–90%) of those treated
with linezolid had a favorable outcome which was de-
fined as either treatment cure or completion [40]. A
prospective open-label phase II to address the efficacy
of linezolid as a substitute for ethambutol in drug-
sensitive PTB is underway in China [41]. In TBM, evi-
dence to support the use of LZD is limited. An observa-
tional study by Li et al. demonstrated favorable clinical
outcomes and a non-significant difference in adverse
events in children with drug-sensitive TBM treated with
linezolid compared to control [42]. However, the study
was a retrospective observational analysis with unblind-
ed assessment of clinical outcomes. Although promis-
ing, further evidence is required to support its use in
children. In adult TBM, there is similar paucity of data;
in a retrospective cohort study of 33 adults with TBM,
the addition of linezolid to a standard regimen led to
more rapid improvement in CSF parameters, recovery of
consciousness and reduction of fever. The study did not
demonstrate a survival benefit but suggests a possible
role for linezolid in adults with severe TBM [43•]. There
has been concern regarding safety of linezolid in partic-
ularly given serious adverse events associated with its use
such as bone marrow suppression, peripheral neuropa-
thy and optic neuropathy. In the aforementioned sys-
temic review, the most common adverse events were
peripheral neuropathy (31%) and anaemia (25%). In
the single RCT included within this meta-analysis, anae-
mia developed mainly during the first 4 months of
treatment, whereas neuropathy developed after a longer
course of treatment (5 months or more) [40].
Bedaquiline became available for the treatment of
MDR-TB in 2013. It is the first antimycobacterial of the
diarylquinoline group and has been shown to have
good early bactericidal activity in PTB [44]. In TBM, a
pharmacokinetic study of a single patient suggests CSF
penetrance may be poor [45]. Nonetheless, others have
hypothesized that thismedication has a potential role in
TBM and warrants further investigation [46].
Host-directed therapies
In TB, there has been much recent interest in adjunctive
host-directed immune interventions to either enhance
protective immunity or regulate pathological tissue-
damaging immunity [47]. Corticosteroids are the most
widely used and researched host-directed therapy. A
number of studies have determined efficacy of cortico-
steroids in TB since their use was first suggested in the
1950s [48–55, 56••]. The largest of these in Vietnam
demonstrated that adjunctive corticosteroids improved
survival in adults and adolescents with TBM [56••]. The
most recent Cochrane review of all published trials of
dexamethasone as an adjunctive treatment in TBM also
demonstrated a survival benefit, but failed to demon-
strate an effect on long termmorbidity [8]. Both this trial
and the Cochrane review highlight the lack of data that
conclusively demonstrates a survival benefit from corti-
costeroids where TBM is associated with HIV-1. Al-
though not powered to address the question of the
efficacy of dexamethasone in HIV-1-associated TBM,
there were 98 HIV-1-infected participants within the
Vietnam trial. Within this subgroup, there was no signif-
icant effect of dexamethasone on the combined end-
point of death and disability or on death alone (strati-
fied relative risk of death 0.78; 95% CI 0.59 to 1.04; p =
0.08). A larger study is underway to address this.
A focus of recent research is the identification of
genetic polymorphisms in immune response genes, in
particular a single polymorphism in the leukotriene A4
hydrolase (LTA4H) promotor which plays a role in the
balance of pro-inflammatory and anti-inflammatory ei-
cosanoids, thereby influencing expression of TNF alpha
[57]. Studies in zebrafish and subsequently in humans
have shown that expression of LTA4H can determine
susceptibility to disease as well as response to cortico-
steroids [58]. In a retrospective analysis of patients en-
rolled to a trial of adjunctive dexamethasone in TBM,
survival benefit was restricted to homozygotes with a TT
genotype of the LTA4H (hyperinflammatory) in contrast
to CC (hypoinflammatory) genotypes where dexameth-
asone was associated with harm [58]. More recently in
an analysis of patients enrolled to a study of intensified
antituberculous regimens and adjunctive dexametha-
sone, LTA4H genotype predicted survival in HIV-1-
uninfected patients with the TT genotype patients signif-
icantly more likely to survive than those with the CC
genotype. In this study, patients with the LT14H TT
genotype had high pro-inflammatory cytokine concen-
trations (IL-1B, IL-1 and IL-6). However, those with CT
and CC genotypes had intermediate or lower concentra-
tions respectively. This may suggest that the suppression
of inflammation by dexamethasone leads to survival
benefit in patients with the TT genotype, however may
be non-beneficial or even harmful in those with CT or
CC genotypes [59]. This highlights the potential role for
individualized immunotherapy where adjunctive corti-
costeroids are given on the basis of pre-treatment
genotyping. Further work to explore this hypothesis in
randomized controlled trials is required.
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Improved understanding of immunopathogenesis in
TBM has led to discovery of target sites for immunother-
apies. The cytokine TNF alpha has been a target in both
animal and human studies. In a rabbit model of TBM,
inhibition of TNF-alpha by use of thalidomide resulted
in survival benefit [60]. In a safety and tolerability study
using thalidomide at escalating doses, thalidomide was
safe and well tolerated as an adjunctive therapy to treat
childrenwith stage 2 TBM [61]. Clinical and radiological
data also suggested improved outcome. The results of
this study supported a phase 3 randomised controlled
trial in paediatric TBM to test thalidomide against pla-
cebo in stage 2 and 3 disease. Thalidomide was given at
a dose of 28mg/kg/day for the first 28 days of treatment.
Forty-seven children were enrolled, of which 30 received
thalidomide. This study was terminated early as all ad-
verse events and deaths occurred in the thalidomide
arm. Debate around the influence of the high dose and
late stage of disease on the adverse outcomes remains
[62]. No further studies have taken place to investigate
what was once a promising treatment option in paedi-
atric TBM; however, recent data suggests thalidomide
and TNF-alpha blockade may still have a role in tuber-
culous mass lesions where treatment with corticoste-
roids has failed [63].
Early (within 2–4 weeks of commencing anti-
tubercular therapy) antiretroviral (ART) therapy of HIV-
1-associated tuberculosis is associated with survival ben-
efit in patients with low CD4 counts [64–66]. A meta-
analysis including 8 randomised controlled trials in PTB
compared survival in patients in whom antiretroviral
therapy was started within 1–4 vs 8–12 weeks. Results
demonstrated a survival benefit in patients newly diag-
nosed with tuberculosis and a CD4 count of less than 50/
mm3 where antiretroviral therapy was commenced with-
in 1–4 weeks of diagnosis [67]. However, initiating such
otherwise life-preserving therapy early during TB treat-
ment may be complicated by more frequent HIV-1-TB-
associated immune reconstitution inflammatory syn-
drome (TB-IRIS). In the CNS, TBM-IRISmay bemarkedly
inflammatory and associates with significant mortality
[68]. In the aforementioned meta-analysis, there was a
twofold increase in TB-associated IRIS in patients treated
early with antiretroviral therapy. This feature, together
with the lack of survival benefit observed in HIV-TBM
patients prescribed early rather than deferred ART [69],
has led to recommendation of a more conservative ap-
proach to the introduction of ART inHIV-1 TBMdeferring
until 4–6 weeks of anti-tubercular therapy. To our knowl-
edge, no research has addressed the question as to
whether the incidence or natural history of HIV-
associated TBM is changing or has changed in light of
more effective anti-HIV therapies of modern times; how-
ever, we feel this would be an important topic for future
research.
Other than corticosteroids, thalidomide and antire-
troviral therapies, there is little clinical trial data to sup-
port efficacy of other host-directed therapies in TBM.
Aspirin has a possible anti-inflammatory as well as
anti-thrombotic role in TBM which is discussed later in
this review. As we understand more of the immune
signaling pathways in the host’s response to tuberculo-
sis, potential therapies continue to emerge. Infliximab is
a TNF-alpha inhibitor which is FDA approved for use in
inflammatory bowel disease, rheumatoid arthritis and
some seronegative arthropathies. Althoughmost reports
of infliximab in TB relate to the reactivation of latent
tuberculosis, there are some case reports where cortico-
steroid has failed to control inflammation yet subse-
quent reintroduction of infliximab has led to a near
complete resolution of symptoms [70, 71]. Other ther-
apies to consider include interleukin receptor 1 inhibi-
tors anakinra (IL-1 alpha and beta) and canakinumab
(IL-1 beta only). The study of TBM-IRIS provides insight
into the inflammatory pathology of TBM. For instance,
an unbiased whole-genome transcriptomic analysis of
peripheral blood has highlighted the role of the innate
immune response demonstrating increased expression
of canonical and non-canonical inflammasome genes
in those developing TBM-IRIS compared to non-IRIS
controls [72•]. This observation provides support for a
dominant role of the innate immune response in
TBM inflammation and suggests novel targets for
immunotherapies.
Supportive therapies
Rich and McCordock were the first to describe the path-
ogenic mechanisms which lead to central nervous sys-
tem tuberculosis [73]. Research since then has enabled
better understanding of the natural history including the
neurological sequelae such as hydrocephalus, vasculitis
leading the cerebral infarction andmetabolic abnormal-
ities especially hyponatremia. Early recognition and
management of these phenomena remains integral to
the treatment of patients with TBM.
Hydrocephalus and raised intracranial pressure
The inflammatory infiltrate within the subarachnoid
space or the ventricular pathwaysmay lead to disruption
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of CSF flow resulting in hydrocephalus. Hydrocephalus
can be communicating (caused by abnormal flow
through the basal cisterns) or non-communicating (usu-
ally a later complication due to obstruction at the level
of the fourth ventricle). Communicating hydrocephalus
is more common and can be managed medically how-
ever may require intervention if progressing. Non-
communicating hydrocephalus required rapid interven-
t i o n . C S F d i v e r s i o n t e c h n i q u e s s u c h a s
ventriculoperitoneal shunts (VPS) and endoscopic third
ventriculostomy are the mainstay of surgical treatment
for hydrocephalus [74]. Evidence as to which technique
is most effective is lacking.
A systematic review of 1038 adults and children with
TBM and hydrocephalus demonstrated good outcome,
defined as Glasgow Outcome Scale 4 or 5 (Table 2) in
58.2% of patients. Good outcomes were observed in
more patients with less severe disease specifically those
found to beGrade I (78.57%) and II (65%) compared to
those with more severe (Grade IV disease) where only
31.5% survived (Table 2). Subgroup analysis demon-
strated that good outcomes occurred in significantly
fewer patients with HIV-1-associated TBM with only
25% patients of patients achieving a good outcome
compared to 61% of HIV-negative patients [77]. In a
study of 30 HIV-1-infected patients with TBM and hy-
drocephalus, participants underwent VP shunt place-
ment and outcomes were compared to age- and
gender-matched HIV-negative controls. Patients were
followed up at two time points, discharge (short term)
and 3 months after VP shunt insertion (long term).
Although short-term outcomes were only marginally
better in the HIV-negative group, long-term outcomes
differed significantly with 66.7% mortality and 76.2%
poor outcome in HIV-positive patients compared to
30.8% mortality and 34.6% poor outcome in the HIV-
negative controls. Their study demonstrated that HIV
seropositivity is an independent predictor of poor out-
come, although they did identify that in patients with
less severe disease at presentation, 80% had good out-
comes. By contrast to previous studies, these results
suggest a role of VP shunting in HIV-associated TBM in
patients with less severe disease [78]. In paediatric TBM,
a recent study showed that there is an association be-
tween the severity of hydrocephalus and CSF immune
biomarkers GFAP and S100B [79]. It remains unclear as
to whether this is due to the secondary compressive
effect on brain parenchyma or whether these inflamma-
tory mediators are involved in the pathogenesis of hy-
drocephalus. Further research is required to establish
best evidence-based practice for the treatment of this
common complication in TBM in particular for HIV-
associated disease.
Although hydrocephalus is the most common cause
of raised ICP, elevated ICP can also be caused by other
pathological processes within the CNS. In TBM,
Table 2. Clinical rating scores in TBM
Glasgow outcome scale [75]
1 Death Severe injury or death without recovery of consciousness
2 Persistent vegetative state Severe damage with prolonged state of
unresponsiveness and a lack of higher mental functions
3 Severe disability Severe injury with permanent need for help with daily living
4 Moderate disability No need for assistance in everyday life,
employment is possible but may require special equipment
5 Low disability Light damage with minor neurological and psychological deficits
Modified Vellore grading scale for TBM-induced hydrocephalus [76]
Grade Glasgow Coma Scale Clinical features
I 15 Headache, vomiting +/− neck stiffness
No neurological deficit
II 15 Neurological deficit present
III 9–14 Neurological deficit may or may not be present
IV 3–8 Neurological deficit may or may not be present
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meningeal pathology may extend into the parenchyma
and lead to encephalitis, whilst obliterative vasculitis
within the vessels leads to infarction. These processes
may result in cytotoxic and vasogenic oedema. The pres-
ence of parenchymal pathology may lead to failure of
cerebral vascular autoregulation. Metabolic abnormali-
ties such as hyponatraemia, hyperthermia and hypercap-
nia can cause further dysregulation. Thus, clinical man-
agement should be directed at the frequent monitoring
and correction of abnormalities in gas exchange and
tissue oxygenation, through mechanical ventilation (if
necessary), meticulous fluid and electrolyte manage-
ment, monitoring and intervention to treat raised intra-
cranial pressure where appropriate as well as adequate
temperature control. When there is no surgical interven-
tion indicated, yet ICP remains high, hyperosmolar
agents most commonly mannitol may be effective yet
a randomised control trial to examine this theory is
required [80, 81].
Hyponatraemia
Hyponatraemia defined as a plasma sodium level G
135 mmol/L occurs in 40–50% of patients with TBM
[82]. Several mechanisms exist. Cerebral salt wasting
(CSW) is characterised by natriuresis, hyponatremia
and volume contraction in response to brain injury
[83]. The syndrome of inappropriate anti-diuretic hor-
mone (SIADH) is also associated with brain injury and
occurs due to excessive release of antidiuretic hormone
from the posterior pituitary gland resulting in inappro-
priate, continued secretion or action of the antidiuretic
hormone arginine vasopressin (AVP) despite normal or
increased plasma volume leading to hyponatraemia
[84]. In a prospective hospital-based study conducted
in India, of 76 patients with TBM, 34 (44.7%) had
hyponatremia due to CSW in 17, SIADH in 3 and mis-
cellaneous causes in 14 [82]. Distinguishing between
CSW and SIADH is critical: their presentations are sim-
ilar, but management is drastically different. By conven-
tion, SIADH is managed by fluid restriction and cerebral
salt wasting by fluid administration. Some suggest that
both conditions can be treated with hypertonic saline
[83], whereas others state that fluid restriction, the tra-
ditional treatment for SIADH, has had little benefit in
meningitis andmight result in worsening hypovolaemia
and harm [84]. This complex and often overlooked
complication in TBM should be further investigated to
define optimal investigation and management.
Tuberculomas
Tuberculomas can occur together with or indepen-
dently of TBM. Clinical presentation depends on site
and includes seizures, focal neurological weakness or
symptoms of raised intracranial pressure due to hy-
drocephalus or mass effect. Tuberculomas common-
ly present as a feature of paradoxical worsening in
patients treated for TB or in HIV-1-infected patients
starting ART. In a randomized study to assess effect
of dexamethasone on TBM-related cerebral MRI
changes in Vietnam, 43 patients receiving either
dexamethasone (n = 24) or placebo (n = 19)
underwent serial MRI scans. The number of patients
with one or more tuberculomas rose from 64% (14
of 22) before treatment to 74% (20 of 27) after
60 days. There was no effect of dexamethasone on
incidence of tuberculoma formation or on resolution
of tuberculomas [85]. The mainstay of treatment
remains anti-tuberculous therapy, the duration of
which is debated. There is lack of evidence in this
area but consensus suggests four anti-tuberculous
drugs for 18 months or until the tuberculoma re-
solves [7]. In some cases, where there is diagnostic
doubt or where the size and anatomical location of
the tuberculoma is causing clinical worsening, surgi-
cal excision may be required. Stereotactic craniotomy
and excision of superficial small tuberculomas and
microsurgery are procedures now used. In cases
where there is no response to dexamethasone, alter-
native anti-inflammatory agents have been tried, par-
ticularly when the tuberculoma involves the optic
chiasm and threatens vision. Some case series suggest
that thalidomide could help to alleviate these prob-
lems [86–88]. Case reports have reported success
with anti-TNF biological agents (such as infliximab)
[70] and IFN-γ treatment [71].
Vasculitis and stroke
Stroke in TBM occurs in 15–57% of patients with
TBM depending on the imaging modality used: CT
reveals stroke in 13–35% [89, 90], MRI in 57% [91,
92]. They are usually multiple, bilateral and occur
most commonly in deep grey matter structures in-
cluding the caudate, anterior thalamus, anterior and
genu of the internal capsule, namely the ‘tubercular
zone’ [93] (see Fig. 1). The macroscopic pathological
appearance in the brain vasculature is that of
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gelatinous fibrocellular leptomeningeal infiltrates
initially enveloping the vessels including the carotid
arteries, middle cerebral arteries and their branches.
Vasculitis within the affected vessels may occur with
intimal proliferation. This process with or without
superadded thrombosis leads to cerebral infarction
[89]. There is no established prevention or treatment
for stroke in TBM. Corticosteroids do not prevent
stroke [56]. Aspirin has antiplatelet, anti-aggregant,
anti-inflammatory and antioxidant properties [94,
95]. In a study of zebrafish, models with the
hyperinflammatory LTA4H phenotype treated with
aspir in showed reduced express ion of pro-
inflammatory eicosanoids and TNF alpha with sub-
sequent modulation of inflammatory response [96].
In a placebo-controlled trial of aspirin in 118 adult
patients with TBM in India, 150 mg OD aspirin was
associated with a significantly lower 3-month mor-
tality and a lower incidence of stroke that was not
significant [97]. These findings suggest the effect of
aspirin may be as much anti-inflammatory as anti-
thrombotic. Following this, a similar study in South
Africa randomized 146 children with TBM to receive
low-dose (75 mg/24 h) (n = 47) or high-dose
(1000 mg/24 h) aspirin. In this trial, there was no
significant effect of aspirin on mortality; however,
there was a significant effect on incidence of new
hemiplegia in those receiving high-dose aspirin
[98]. Although more effective therapies are now
available for acute treatment and secondary preven-
tion of ischaemic stroke associated with non-
infectious vascular risk factors, aspirin an inexpen-
sive well-tolerated drug remains the most commonly
used treatment worldwide. Further large-scale ran-
domized controlled trials are required to explore its
role in reducing inflammation and vascular compli-
cations in TBM.
Conclusions and research priorities
& The neurological presentations of tuberculosis are
the most lethal and under-researched manifesta-
tions of TB which remains a major global health
problem.
& Current anti-tuberculous therapy regimens for TBM
are based on those which are efficacious in PTB but
do not consider the differing efficacy of drugs across
the BBB. Further research is required to investigate
the safety and efficacy of intensified therapy regi-
mens and newer anti-tuberculous agents to treat
CNS tuberculosis.
Fig. 1. Computerised tomography (CT) of the head with evidence of probable perforator territory infarction on the left in an HIV-1-
infected patient with tuberculous meningitis.
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Fig. 2. Treatment algorithm for patients with tuberculous meningitis.
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& Corticosteroids have proven mortality benefit
except in HIV-associated TBM where as yet no
sufficiently powered study has been able to
prove benefit or lack thereof. More research is
required to develop and evaluate novel host-
directed therapies. Immune response phenotypes
and genetic polymorphisms may direct individual-
ized immune therapies andmediators of the innate
immune response may provide targets for the de-
velopment novel therapies.
& Stroke is a major cause of morbidity and mortality
in TBM. Recent studies have shown a potential
benefit of aspirin in the prevention of stroke as well
as in the modulation of the host immune response
in TBM. This requires further investigation in large
phase 3 clinical trials.
& There is currently no significant evidence base to
guide management of hydrocephalus in HIV-1-
infected TBM. A large randomized clinical trial is
required to investigate outcomes comparing
available CSF diversion techniques in this par-
ticularly vulnerable subgroup of patients.
& A treatment algorithm provided in this paper
gives a practical holistic approach to the man-
agement of patients with tuberculous meningitis
(Fig. 2).
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